Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Jing Chen, Doctor
CONTACT
Lead
BGI, China
With
This is a single arm, open label and non-randomized clinical study with two parts. In Part A, 6 subjects with advanced solid tumors will be enrolled to assess the safety and explore maximum tolerated dose(MTD) or recommended dose of Neo-T. Depending on results in Part A, the study may proceed to Part B, where 15 subjects with advanced solid tumors will be enrolled to evaluate the effect of Neo-T.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted